CDK12 INHIBITION REVERSES DE NOVO AND ACQUIRED PARP INHIBITOR RESISTANCE IN BRCA WILD-TYPE AND MUTATED MODELS OF TRIPLE-NEGATIVE BREAST CANCER

Although poly (ADP-ribose) polymerase (PARP) inhibitors are active in homologous recombination (HR)-deficient cancers, their utility is limited by acquired resistance following restoration of HR. Here, we report that dinaciclib, an inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5 and 9, addition...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cell Rep
Glavni autori: Johnson, Shawn F., Cruz, Cristina, Greifenberg, Ann Katrin, Dust, Sofia, Stover, Daniel G., Chi, David, Primack, Benjamin, Cao, Shiliang, Bernhardy, Andrea J., Coulson, Rhiannon, Lazaro, Jean-Bernard, Kachupurakkal, Bose, Sun, Heather, Unitt, Christine, Moreau, Lisa A., Sarosiek, Kristopher A., Scaltriti, Maurizio, Juric, Dejan, Baselga, José, Richardson, Andrea L., Rodig, Scott J., D’Andrea, Alan D., Balmaña, Judith, Johnson, Neil, Geyer, Matthias, Serra, Violeta, Lim, Elgene, Shapiro, Geoffrey I.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5176643/
https://ncbi.nlm.nih.gov/pubmed/27880910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2016.10.077
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items